Cyclophosphamide (generic), Cytoxan Newswire (Page 10)

Cyclophosphamide (generic), Cytoxan Newswire (Page 10)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 10)

Results 181 - 200 of 620 in Cyclophosphamide (generic), Cytoxan

  1. 10-Year Follow-Up Analysis Of BCIRG-006 Study ByRead the original story

    Dec 10, 2015 | BioSpace

    The analysis also showed that this efficacy benefit is very similar in the anthracycline and non-anthracycline based, trastuzumab-containing regimens; however, the non-anthracycline regimen was associated with an important improvement in long-term cardiac safety . The BCIRG-006 trial evaluated three regimens after initial surgery: 4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of docetaxel versus 4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of docetaxel and one year of Herceptin versus a non-anthracycline regimen of 6 cycles of docetaxel plus carboplatin and one year of trastuzumab .

    Comment?

  2. Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancerRead the original story w/Photo

    Dec 11, 2015 | Medical News

    Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. "Luminal A is a relatively common subtype of breast cancer, and is defined by high expression of hormone receptors [estrogen receptor and progesterone receptor ], and low expression of the cell-growth marker Ki67 and the oncoprotein HER2.

    Comment?

  3. Recent Investment Analysts' Ratings Updates for Cellectis SARead the original story w/Photo

    Dec 10, 2015 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Cellectis SA in the last few weeks: 12/7/2015 - Cellectis SA had its "buy" rating reaffirmed by analysts at Oppenheimer. They now have a $65.00 price target on the stock.

    Comment?

  4. Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapyRead the original story w/Photo

    Dec 10, 2015 | Medical News Today

    Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy , according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. "Luminal A is a relatively common subtype of breast cancer, and is defined by high expression of hormone receptors [ estrogen receptor and progesterone receptor ], and low expression of the cell-growth marker Ki67 and the oncoprotein HER2.

    Comment?

  5. Puma Biotech Announces Results Of Phase II Trial Of PB272 In...Read the original story

    Dec 9, 2015 | BioSpace

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from a randomized Phase II clinical trial of Puma's investigational drug PB272 in the neoadjuvant treatment of locally advanced HER2-positive breast cancer were presented at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. The presentation entitled "NSABP FB-7: A Phase II Randomized Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Trastuzumab or Neratinib or Trastuzumab and Neratinib Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer" will be presented today at the poster discussion session.

    Comment?

  6. Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapyRead the original story w/Photo

    Dec 9, 2015 | PhysOrg Weblog

    Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. "Luminal A is a relatively common subtype of breast cancer, and is defined by high expression of hormone receptors [estrogen receptor and progesterone receptor ], and low expression of the cell-growth marker Ki67 and the oncoprotein HER2.

    Comment?

  7. Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapyRead the original story w/Photo

    Dec 8, 2015 | EurekAlert!

    Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. "Luminal A is a relatively common subtype of breast cancer, and is defined by high expression of hormone receptors [estrogen receptor and progesterone receptor ], and low expression of the cell-growth marker Ki67 and the oncoprotein HER2.

    Comment?

  8. Kite Pharma Announces Clinical Biomarker Results Of Anti-CD19 Car T...Read the original story

    Dec 7, 2015 | BioSpace

    Kite Pharma, Inc. today announced clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor T cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma enrolled in an ongoing phase 1-2 clinical trial at the National Cancer Institute , which is being conducted under a Cooperative Research and Development Agreement between Kite and the NCI. In this clinical trial, patients with a range of B cell cancers were conditioned with cyclophosphamide and fludarabine prior to receiving anti-CD19 CAR T cell therapy.

    Comment?

  9. ASH- CAR-T Struggles To Travel Beyond LeukaemiaRead the original story w/Photo

    Dec 8, 2015 | Seeking Alpha

    If ASH was another scientific meeting where interest in CAR-T therapies mounted, an obvious theme was just how much more work still needs to be done to get beyond the relatively accessible low-hanging fruit of acute lymphoblastic leukaemia . And that goes for all the big players Novartis , Juno and Kite Pharma whose leading CD19 -directed projects featured in several presentations over the conference.

    Comment?

  10. Starving Cancer, Nourishing UnderstandingRead the original story w/Photo

    Dec 8, 2015 | Health News Digest

    Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own - it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

    Comment?

  11. Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015Read the original story w/Photo

    Dec 7, 2015 | Medical News

    Additional Presentation: Phase 2 Results From an Investigational study of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology , showing that treatment with NINLARO capsules is effective in extending progression free survival with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

    Comment?

  12. Juno??'s Investigational Car T Product Candidates JCAR014 And...Read the original story

    Dec 6, 2015 | BioSpace

    Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, that clinical data from a chimeric antigen receptor T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia . Results will be presented in an oral presentation today at the 54th Annual Meeting of the American Society of Hematology in Orlando.

    Comment?

  13. Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study For NINLARO...Read the original story

    Dec 6, 2015 | BioSpace

    Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology , showing that treatment with NINLAROA capsules is effective in extending progression free survival with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. The TOURMALINE-MM1 trial is an international, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate once-weekly oral ixazomib plus lenalidomide and dexamethasone compared to placebo plus lenalidomide and dexamethasone.

    Comment?

  14. Kite Pharma Says Will Issues Results of Anti-CD19 Car T Cell Therapy at Ash MeetingRead the original story

    Dec 7, 2015 | Benzinga

    Kite Pharma, Inc. today announced clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor T cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma enrolled in an ongoing phase 1-2 clinical trial at the National Cancer Institute , which is being conducted under a Cooperative Research and Development Agreement between Kite and the NCI. In this clinical trial, patients with a range of B cell cancers were conditioned with cyclophosphamide and fludarabine prior to receiving anti-CD19 CAR T cell therapy.

    Comment?

  15. Multiple myeloma: Takeda presents data from phase 3 TOURMALINE-MM1 study for NINLARORead the original story w/Photo

    Dec 7, 2015 | Medical News Today

    Takeda Pharmaceutical Company Limited has announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology , showing that treatment with NINLARO capsules is effective in extending progression free survival with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma . The TOURMALINE-MM1 trial is an international, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate once-weekly oral ixazomib plus lenalidomide and dexamethasone compared to placebo plus lenalidomide and dexamethasone.

    Comment?

  16. Immune dysfunction in mother may be linked with autism, say researchersRead the original story w/Photo

    Dec 5, 2015 | Examiner.com

    Kratochvil, Vera. Mother Kissing Baby [photograph] Retrieved from: A recent, large-scale study showed that in about 10 percent of mothers, there are antibodies in their bloodstream that react with the proteins in the brains of their infants.

    Comment?

  17. Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefitRead the original story w/Photo

    Dec 4, 2015 | Medical News Today

    Pertuzumab is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer was already investigated by the German Institute for Quality and Efficiency in Health Care in a dossier assessment in 2013.

    Comment?

  18. Neurotoxic effects of chemotherapies on cognition in breast cancer survivorsRead the original story w/Photo

    Dec 3, 2015 | PhysOrg Weblog

    Cancer-related cognitive impairment is often referred to as 'chemobrain' and anthracycline-based chemotherapy may have greater negative effects on particular cognitive domains and brain network connections than nonanthracycline-based regimens, according to an article published online by JAMA Oncology . Chemotherapy for breast cancer is often associated with cognitive problems in patients.

    Comment?

  19. Primary Systemic Amyloidosis Market Global Industry Analysis, Growth, Trends and Forecast 2020Read the original story w/Photo

    Dec 3, 2015 | SBWire

    Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis.

    Comment?

  20. Immunovaccine's DPX-Survivac Induces an Immune Response in Diffuse Large B Cell LymphomaRead the original story

    Dec 2, 2015 | Sys-Con Media

    This early result demonstrates that DPX-Survivac, Immunovaccine's lead cancer immune therapy, can induce immune responses in hematologic cancers, such as DLBCL. Researchers observed changes in tumor-infiltrating T cells following administration of the DPX-Survivac therapy, which correlated with an immune response produced by DPX-Survivac and detected in the blood.

    Comment?